JP2003500360A - ボロプロリン化合物類を含む抗癌剤 - Google Patents

ボロプロリン化合物類を含む抗癌剤

Info

Publication number
JP2003500360A
JP2003500360A JP2000619438A JP2000619438A JP2003500360A JP 2003500360 A JP2003500360 A JP 2003500360A JP 2000619438 A JP2000619438 A JP 2000619438A JP 2000619438 A JP2000619438 A JP 2000619438A JP 2003500360 A JP2003500360 A JP 2003500360A
Authority
JP
Japan
Prior art keywords
cancer
drug
subject
agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000619438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500360A5 (fr
Inventor
ピー． ウォールナー，バーバラ
ミラー，グレン
Original Assignee
ポイント セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポイント セラピューティクス， インコーポレイテッド filed Critical ポイント セラピューティクス， インコーポレイテッド
Publication of JP2003500360A publication Critical patent/JP2003500360A/ja
Publication of JP2003500360A5 publication Critical patent/JP2003500360A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000619438A 1999-05-25 2000-05-25 ボロプロリン化合物類を含む抗癌剤 Pending JP2003500360A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13586199P 1999-05-25 1999-05-25
US60/135,861 1999-05-25
PCT/US2000/014505 WO2000071135A1 (fr) 1999-05-25 2000-05-25 Agents anti-tumorales contenant des composes de boroproline

Publications (2)

Publication Number Publication Date
JP2003500360A true JP2003500360A (ja) 2003-01-07
JP2003500360A5 JP2003500360A5 (fr) 2007-07-19

Family

ID=22470056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000619438A Pending JP2003500360A (ja) 1999-05-25 2000-05-25 ボロプロリン化合物類を含む抗癌剤

Country Status (6)

Country Link
EP (1) EP1187619A1 (fr)
JP (1) JP2003500360A (fr)
AU (1) AU781897B2 (fr)
CA (1) CA2373643A1 (fr)
HK (1) HK1046846A1 (fr)
WO (1) WO2000071135A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533727A (ja) * 2011-11-22 2014-12-15 トラスティーズ オブ タフツ カレッジ 樹状細胞癌ワクチンのための小分子エンハンサー

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CN1479622A (zh) 2000-10-12 2004-03-03 联合使用阿普里汀和肌肉保护剂来治疗癌症
WO2003037373A1 (fr) * 2001-10-31 2003-05-08 Medical Research Council Utiilisation d'un antagoniste du recepteur ep2 ou ep4 et/ou d'un inhibiteur de la cox-1 pour traiter un cancer cervical
EP1469873A4 (fr) * 2001-11-26 2007-10-03 Tufts College Inhibiteurs peptidomimetiques d'enzymes de clivage post-proline
JP2003267966A (ja) * 2002-03-13 2003-09-25 Pola Chem Ind Inc フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤
EP1578434A2 (fr) * 2002-07-09 2005-09-28 Point Therapeutics, Inc. Procedes et compositions ayant trait a des composes d'isoleucine boroproline
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2556056A1 (fr) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur de gpr119 et traitement de troubles associés
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
WO2012135570A1 (fr) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012145603A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012145604A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
US20200030411A1 (en) * 2016-09-21 2020-01-30 Agency For Science, Technology And Research Methods and Compositions for Inhibiting Skin Inflammation and Determining Cancer Susceptibility
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
CN115779148B (zh) * 2021-09-09 2024-02-23 中国科学院福建物质结构研究所 一种牙种植体表面涂层及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02268118A (ja) * 1989-04-07 1990-11-01 Mitsubishi Gas Chem Co Inc 免疫賦活剤
WO1998050046A1 (fr) * 1997-05-07 1998-11-12 Trustees Of Tufts College Utilisation d'un inhibiteur du cd26 pour preparer un medicament traitant le vih

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328936A (en) * 1993-02-01 1994-07-12 Rohm And Haas Company Polymerization process for making porous polymeric particles
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5767242A (en) * 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
PT1084129E (pt) * 1998-06-05 2003-06-30 Point Therapeutics Inc Compostos de boroprolina ciclica
KR20010079669A (ko) * 1998-08-21 2001-08-22 바바라 피. 월너 기질 활성의 조절

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02268118A (ja) * 1989-04-07 1990-11-01 Mitsubishi Gas Chem Co Inc 免疫賦活剤
WO1998050046A1 (fr) * 1997-05-07 1998-11-12 Trustees Of Tufts College Utilisation d'un inhibiteur du cd26 pour preparer un medicament traitant le vih

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533727A (ja) * 2011-11-22 2014-12-15 トラスティーズ オブ タフツ カレッジ 樹状細胞癌ワクチンのための小分子エンハンサー
JP2017214420A (ja) * 2011-11-22 2017-12-07 トラスティーズ オブ タフツ カレッジ 樹状細胞癌ワクチンのための小分子エンハンサー

Also Published As

Publication number Publication date
CA2373643A1 (fr) 2000-11-30
AU781897B2 (en) 2005-06-23
AU5292700A (en) 2000-12-12
HK1046846A1 (zh) 2003-01-30
EP1187619A1 (fr) 2002-03-20
WO2000071135A1 (fr) 2000-11-30

Similar Documents

Publication Publication Date Title
JP2003500360A (ja) ボロプロリン化合物類を含む抗癌剤
US7259138B2 (en) Anti-tumor agents
JP5075927B2 (ja) 固形腫瘍を予防および治療するための方法および組成物
US11433136B2 (en) Polyacetal polymers, conjugates, particles and uses thereof
KR101483802B1 (ko) 외투층 세포 림프종의 치료에 있어서 3-(4-아미노-1-옥소-1,3-디히드로-이소인돌-2-일)-피페리딘-2,6-디온의 용도
CN1191485A (zh) 用氨基咪唑甲酰胺和5-氨基或取代的氨基1,2,3-三唑的盐治疗和预防肿瘤
US20050267027A1 (en) Use of erythropoietin for treatment of cancer
WO2021012886A1 (fr) Composition pharmaceutique combinée antinéoplasique et son application
Su et al. Role of CXCR4 in the progression and therapy of acute leukaemia
US20210008173A1 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
Rajkumar Thalidomide in the treatment of multiple myeloma
US8232318B2 (en) Approaches to treat cancer using HB-EGF inhibitors
Zhang et al. Anti-angiogenic therapies in cancer clinical trials
EP1806138A1 (fr) Agents anti-tumoraux comprenant des dérivés de la boroproline
AU2005211682A1 (en) Anti-tumor comprising boroproline compounds
US20240216465A1 (en) Method for treating refractory brain tumor
US12000829B2 (en) Selection of patients for combination therapy
CA3230917A1 (fr) Peptides d'endostatine pour le traitement de tumeurs, d'une fibrose et d'une lesion pulmonaire aigue
Korpela Improving Cancer Radiotherapy Outcomes with Vasculotide, an Angiopoietin-1 Mimetic
Teicher 17 Potentiation of Cytotoxic Cancer

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308